Why the study?
Half of reported KCNH2 variants in ClinVar are classified as variants of uncertain significance, creating a need for functional phenotyping to determine the significance of incidentally identified variants.
The described high-throughput functional genomics assay enables rapid assessment of the functional significance of KCNH2 variants, which is critical for interpreting variants of uncertain significance.
Answers are grounded in this paper and cite their sources.
May accelerate research screening of KCNH2 variants; leaves open clinical translation and should not yet alter practice.
KCNH2 is one of the 59 medically actionable genes recommended by the American College of Medical Genetics for reporting of incidental findings from clinical genomic sequencing. However, half of the reported KCNH2 variants in the ClinVar database are classified as variants of uncertain significance. In the absence of strong clinical phenotypes, there is a need for functional phenotyping to help decipher the significance of variants identified incidentally. Here, we report detailed methods for assessing the molecular phenotype of any KCNH2 missense variant. The key components of the assay include quick and cost-effective generation of a bi-cistronic vector to co-express Wild-type (WT) and any KCNH2 variant allele, generation of stable Flp-In HEK293 cell lines and high-throughput automated patch clamp electrophysiology analysis of channel function. Stable cell lines take 3–4 weeks to produce and can be generated in bulk, which will then allow up to 30 variants to be phenotyped per week after 48 h of channel expression. This high-throughput functional genomics assay will enable a much more rapid assessment of the extent of loss of function of any KCNH2 variant.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: